Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison

@article{Motaghi2019EtrolizumabVI,
  title={Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison},
  author={E. Motaghi and Masoumeh Ghasemi-Pirbaluti and M. Zabihi},
  journal={Pharmacological Research},
  year={2019},
  volume={139},
  pages={120–125}
}
  • E. Motaghi, Masoumeh Ghasemi-Pirbaluti, M. Zabihi
  • Published 2019
  • Medicine
  • Pharmacological Research
  • Objectives: There is still a need to develop new effective medications for the treatment of ulcerative colitis, particularly for patients who are intolerant or resistant to first line therapies. This article compared the efficacy and safety of etrolizumab and infliximab in moderate to severe ulcerative colitis. Methods: This meta‐analysis was performed according to the PRISMA statement protocol. A systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran… CONTINUE READING
    4 Citations

    Figures, Tables, and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Recent advances in inflammatory bowel disease therapy.
    • A. Binienda, J. Fichna, M. Salaga
    • Medicine
    • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
    • 2020

    References

    SHOWING 1-10 OF 26 REFERENCES
    An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
    • 11
    • Highly Influential
    • PDF
    Etrolizumab for ulcerative colitis: the new kid on the block?
    • 5
    Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
    • 27
    The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients
    • 148
    Biologic agents for IBD: practical insights
    • 160
    • Highly Influential